Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

By D. Hesselink, R. V. Schaik, I. Heiden, M. Werf, P. Gregoor, J. Lindemans, W. Weimar, T. Gelder. Clinical pharmacology and therapy, 2003

700 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “…for CYP3A5⁎3 compared with those carrying CYP3A5⁎1 alleles, with the level in the former being higher than the latter (Macphee et al., 2002; Hesselink et al., 2003; Goto et al., 2004; Haufroid et al., 2004; Tsuchiya et al., 2004;Macphee et al., 2005;Mourad et al., 2005; Tada et al.,…”
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “Associations with CYP3A5 genotype were reported, for example, for the immunosuppressant tacrolimus (Hesselink et al., 2003; Anglicheau et al., 2007; Elens et al., 2011b); the antihypertensive verapamil (Jin et al.”